Akebia Therapeutics (AKBA) Operating Expenses (2013 - 2026)
Akebia Therapeutics (AKBA) posted quarterly Operating Expenses of $45.9 million for Q1 2026, up 26.94% year-over-year from $36.2 million in Q1 2025, and down 14.34% quarter-over-quarter from $53.6 million in Q4 2025.
Akebia Therapeutics (AKBA) Operating Expenses (2013 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has reported Operating Expenses for 14 consecutive years, with $45.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses rose 26.94% year-over-year to $45.9 million; the TTM figure through Mar 2026 stood at $183.0 million (up 23.86% YoY), while the FY2025 annual figure was $173.2 million, up 17.47% from the prior year.
- Operating Expenses fell to $45.9 million in Q1 2026 per AKBA's latest filing, from $53.6 million in the prior quarter.
- Across five years, Operating Expenses topped out at $88.8 million in Q1 2022 and bottomed at $35.3 million in Q2 2024.
- Historically, Operating Expenses has averaged $48.3 million across 5 years, with a median of $44.9 million in 2025.
- Annual changes were most pronounced in 2023 — Operating Expenses plunged 48.89% — and 2025, when it jumped 32.64%.
- Akebia Therapeutics' Operating Expenses stood at $64.1 million in 2022, then slumped by 43.58% to $36.2 million in 2023, then advanced by 11.84% to $40.4 million in 2024, then surged by 32.64% to $53.6 million in 2025, then slipped by 14.34% to $45.9 million in 2026.
- Business Quant data shows AKBA's Operating Expenses at $45.9 million in Q1 2026, $53.6 million in Q4 2025, and $44.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | 1.29 Bn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 215.00 Mn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | -2.85 Bn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | 452.50 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 1.45 Bn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 807.50 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 550.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Akebia Therapeutics | 247.60 Mn | 92.06 Mn | 38.70 Mn | 45.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 45.03 Mn |
| Mar 31, 2026 | 45.95 Mn |
| Dec 31, 2025 | 53.64 Mn |
| Sep 30, 2025 | 44.93 Mn |
| Jun 30, 2025 | 38.46 Mn |
| Mar 31, 2025 | 36.20 Mn |
| Dec 31, 2024 | 40.44 Mn |
| Sep 30, 2024 | 35.77 Mn |
| Jun 30, 2024 | 35.33 Mn |
| Mar 31, 2024 | 35.94 Mn |
| Dec 31, 2023 | 36.16 Mn |
| Sep 30, 2023 | 37.07 Mn |
| Jun 30, 2023 | 48.09 Mn |
| Mar 31, 2023 | 45.41 Mn |
| Dec 31, 2022 | 64.08 Mn |
| Sep 30, 2022 | 60.84 Mn |
| Jun 30, 2022 | 73.69 Mn |
| Mar 31, 2022 | 88.85 Mn |
| Dec 31, 2021 | 75.39 Mn |
| Sep 30, 2021 | 87.70 Mn |